Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00089804
Status:
TERMINATED
Last Update Posted:
2009-04-01
First Post:
2004-08-13
Brief Title:
Study of LJP 394 in Lupus Patients With History of Renal Disease
Sponsor:
La Jolla Pharmaceutical Company
Organization:
La Jolla Pharmaceutical Company
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Three-Arm Parallel-Group Multicenter Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus SLE Patients With a History of Renal Disease
Status:
TERMINATED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Interim efficacy analysis indicated it would be futile to continue study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ASPEN
Brief Summary:
The primary purpose of this study is to determine whether abetimus sodium is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None